<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20230807059069N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-24</date_registration>
      <primary_sponsor>Mazandaran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Galenos Barij Syrup on nausea and vomiting caused by chemotherapy with strong emetic ability compared to standard treatment.</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effectiveness of Galenos Barij Syrup on preventing nausea and vomiting in patients referred to outpatient chemotherapy receiving the regime with high emetic chemotherapy (HEC) compared to the standard regime</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>56</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71862</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Random allocation will be done by block method (Randomization Block) with a block size of four and using Sealed Envelope online software at the address https://www.sealedenvelope.com at an individual level and by an epidemiologist researcher who is a member of the research team. In this site, which is an online software for creating random allocation, the create list option is selected through the randomization menu, and then the required parameters such as groups A and B, the number of blocks, which is 4, and the total number of samples will be entered. And finally the random allocation list will be created. A sealed non-transparent envelope will be used for concealment. Researchers enroll eligible participants after the baseline assessment, then remove and open each envelope in the order that corresponds to the participant's initial assessment order, and assign the eligible participant to either the intervention group or the control group.</study_design>
      <phase>3</phase>
      <hc_freetext>Chemotherapy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In our current study, we used 5-10 cc barrage syrup based on person weight. Barrage syrup is containing fruit (Cydonia oblonga), ginger (Zingiberofficinale), vinegar and honey as an adjunctive treatment to the standard treatment containing a 5-HT3R inhibitor (Granicitron (Kytril brand)), NK1 receptor antagonist ( We will use aperpitant (amand brand name) and dexamethasone.The anti-nausea effect of this product is on the one hand due to the presence of "Bah" fruit extract and on the other hand due to the presence of ginger. It becomes natural. Also, consuming "beh" after meals helps to eliminate indigestion and improve the digestive condition.Natural honey has antimicrobial and antibacterial properties and other enzymes that produce a small amount of hydrogen peroxide. Hydrogen peroxide, in turn, relieves you of indigestion. Natural honey contains the enzymes invertase, catalase, peroxidase, glucose oxidase, phosphatase and enolase acid, which help in proper digestion. It also contains potassium, which relieves nausea and inflammation of the lining of the esophagus and helps the stomach to neutralize acids. Honey is anti-nausea, and regular consumption of honey affects the muscles of the stomach and helps with proper digestion. . Also, natural honey stabilizes the content of hydrochloric acid in the body.Being rich in some vitamins, vinegar is very effective in the health of the digestive system and its elimination of toxins. It also has a significant effect in the treatment of some diseases and disorders of the digestive system, such as better digestion of food and reduction of nausea. Intervention 2: Control group: According to the clinical guidelines for the prevention of CINV in people undergoing chemotherapy with a high risk of emesis (HEC), a combination of 5-HT3 receptor antagonist (Granicitron 3 mg), NK-1 receptor antagonist (Aprepitant 125 mg daily) and dexamethasone 8 mg will be used as the standard before chemotherapy and a combination of aprepitant and dexamethasone will be given on days 2 and 3 and dexamethasone on day 4.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only a part of the data, such as the information related to the main result or the like, can be shared.

When:
Since 2025

To whom:
It will be available only to researchers working in academic and scientific institutions

Conditions:
There are no other conditions for the use of data or documentation. No analysis is allowed on the delivered data.

Where to obtain:
MOHAMMAD MEHDI VAZIRI
drmmvaziri@gmail.com

How to obtain:
After communicating through the above email, the desired request will be submitted

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Mehdi Vaziri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi Ave.</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>48816633131</zip>
        <telephone>+98 11 3336 4044</telephone>
        <email>drmmvaziri@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Mehdi Vaziri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Razi</address>
        <city>Sari</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4816633131</zip>
        <telephone>+98 11 3336 4044</telephone>
        <email>drmmvaziri@gmail.com</email>
        <affiliation>Mazandaran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>People over the age of 18
Patients under high emetogenic chemotherapy regimens (HEC) referring to outpatient chemotherapy at Imam Khomeini Hospital and Baghban Complex</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to ginger
Ginger consumption within a week before the start of the intervention
Users of warfarin, heparin and aspirin drugs
History of neurological diseases, history of seizures and epilepsy, history of blood disorders
Patients with bowel obstruction or brain or bowel metastasis
Lack of consent to participate in the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Z51.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Encounter for Antineoplastic Chemotherapy and Immunotherapy</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In our current study, we used 5-10 cc barrage syrup based on person weight. Barrage syrup is containing fruit (Cydonia oblonga), ginger (Zingiberofficinale), vinegar and honey as an adjunctive treatment to the standard treatment containing a 5-HT3R inhibitor (Granicitron (Kytril brand)), NK1 receptor antagonist ( We will use aperpitant (amand brand name) and dexamethasone.The anti-nausea effect of this product is on the one hand due to the presence of "Bah" fruit extract and on the other hand due to the presence of ginger. It becomes natural. Also, consuming "beh" after meals helps to eliminate indigestion and improve the digestive condition.Natural honey has antimicrobial and antibacterial properties and other enzymes that produce a small amount of hydrogen peroxide. Hydrogen peroxide, in turn, relieves you of indigestion. Natural honey contains the enzymes invertase, catalase, peroxidase, glucose oxidase, phosphatase and enolase acid, which help in proper digestion. It also contains potassium, which relieves nausea and inflammation of the lining of the esophagus and helps the stomach to neutralize acids. Honey is anti-nausea, and regular consumption of honey affects the muscles of the stomach and helps with proper digestion. . Also, natural honey stabilizes the content of hydrochloric acid in the body.Being rich in some vitamins, vinegar is very effective in the health of the digestive system and its elimination of toxins. It also has a significant effect in the treatment of some diseases and disorders of the digestive system, such as better digestion of food and reduction of nausea.</i_keyword>
      <i_keyword>Control group: According to the clinical guidelines for the prevention of CINV in people undergoing chemotherapy with a high risk of emesis (HEC), a combination of 5-HT3 receptor antagonist (Granicitron 3 mg), NK-1 receptor antagonist (Aprepitant 125 mg daily) and dexamethasone 8 mg will be used as the standard before chemotherapy and a combination of aprepitant and dexamethasone will be given on days 2 and 3 and dexamethasone on day 4.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The Rhodes Index questionnaire will evaluate the main outcome of the study. This tool (Nausea and Vomiting Index) is designed as a 5-point Likert scale (score 0-4). The final score range will vary between 0-32. In order to interpret the scores obtained from the questionnaire, the average scores related to nausea and vomiting in each group were calculated. The Rhodes questionnaire will be completed daily.All patients were provided with a daily side effect checklist at the first visit to the outpatient chemotherapy clinic. Using the checklist, patients will record daily their nausea with a numerical rating scale (NRS) (0-10) and the number of times or episodes of vomiting up to 7 days after chemotherapy. The physician implementing the plan will record the amount of control of nausea and vomiting in the medical record after confirming the data or hearing the results of the patients at the next visit. Complete protection from nausea (NRS &lt;1) and vomiting (no episodes) during the acute (within 24 hours after chemotherapy) and delayed (within 2 to 7 days after chemotherapy) episodes in patients receiving the first cycle of chemotherapy or will be evaluated in general cycles of chemotherapy. Timepoint: Patients will record daily nausea (0-10) and the number of times or episodes of vomiting up to 7 days after chemotherapy. Method of measurement: Rhodes Index Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mazandaran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-10</approval_date>
        <contact_name>Imam (RA) Sari Educational and Medical Hospital - Mazandaran University of Medical Sciences (Researc</contact_name>
        <contact_address>Imam Khomeini Hospital, Razi St. Sari Mazandaran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
